La chaîne d'options affiche les données clés des options sur actions de Phillips Edison & Co à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Phillips Edison & Co..

Phillips Edison & Co (NASDAQ:PECO) Stock, Chaîne d'Options

Phillips Edison & Co

Phillips Edison

Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interests, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on market of expertise designed to optimize property value and consistently deliver a great shopping experience.

Phillips Edison & Company, Inc. - Common Stock

Phillips Edison & Co Inc

News

EPRX

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled RESOLVE Trial for Eosinophilic Esophagitis, Targeting Pivotal Study Readiness by Q3 2026

CRVO

CervoMed To Present Results From RewinD-LB Phase 2b Study Of Neflamapimod In Dementia With Lewy Bodies, At AAIC 2025

Biotech

Events

General

CervoMed To Present At Alzheimer's Association International Congress 2025 On July 27

<a href="https://www.globenewswire.com/Tracker?data=Sjm7HxugM0aKuCdtig1s0NCVhX9IUz-W8Mp8zVyUhHXfQqg2WbsApG6GwJU8XSA3lZstKPsqrfZBYjvWSvGs2veBvziXAsBoPL84_T7GNdw=">Plymouth Industrial REIT</a>, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLYM#NYSE">PLYM</a>) (the "Company" or "Plymouth") provided an activity update for the second quarter of 2025. The Company also announced details for its second quarter earnings conference call and webcast to be held on August 7, 2025.
Leasing Activity Leases commencing during the second quarter ended June 30, 2025, which have terms of at least six months, totaled an aggregate of 1,453,757 square feet. These leases included:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Leases Commenced</td>
<td>Type</td>
<td>Square Footage</td>
<td>Percent</td>
<td colspan="3">Expiring Rent</td>
<td colspan="3">New Rent</td>
<td>Cash Rent Spread</td>
</tr>
<tr>
<td>Q2</td>
<td>Renewal</td>
<td>1,159,623</td>
<td>79.8%</td>
<td>$</td>
<td>5.00</td>
<td>$</td>
<td>5.45</td>
<td>9.0%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>New</td>
<td>294,134</td>
<td>20.2%</td>
<td>$</td>
<td>4.92</td>
<td>$</td>
<td>5.61</td>
<td>14.0%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Total</td>
<td>1,453,757</td>
<td>100%</td>
<td>$</td>
<td>4.98</td>
<td>$</td>
<td>5.48</td>
<td>10.0%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
An additional 239,500 square feet has been leased on a short-term basis with auto-renewals and landlord kick-out options.
Total executed leases commencing during 2025, which had terms of at least six months, totaled an aggregate of 5,811,172 square feet. These leases, which represent 67.5% of total 2025 expirations, include:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>2025 Commencements</td>
<td>Type</td>
<td>Square Footage</td>
<td>Percent</td>
<td colspan="3">Expiring Rent</td>
<td colspan="3">New Rent&nbsp;</td>
<td>Cash Rent Spread</td>
</tr>
<tr>
<td>Renewal</td>
<td>4,095,835</td>
<td>70.5%</td>
<td>$</td>
<td>4.47</td>
<td>$</td>
<td>5.13</td>
<td>14.7%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>New</td>
<td>1,715,337</td>
<td>29.5%</td>
<td>$</td>
<td>4.27</td>
<td>$</td>
<td>4.64</td>
<td>8.7%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Total</td>
<td>5,811,172</td>
<td>100%</td>
<td>$</td>
<td>4.41</td>
<td>$</td>
<td>4.98</td>
<td>13.0%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Excluding the effect of the St. Louis Lease (as defined below), which commenced in the first quarter, rental rates under these leases would have reflected a 15.8% increase with new leases reflecting a 19.9% increase on a cash basis. The Company executed a two-year lease at its 769,500-square-foot Class A industrial building in the Metro East submarket of St. Louis, Missouri that commenced on January 15, 2025 (the "St. Louis Lease"). The lease is for 600,000 square feet during the first year and 450,000 square feet during the second year with a major international logistics service provider. This deal was done on an "as is" basis with no abatements making it attractive from a net lease rate perspective. While we continue to actively market the balance of the building, the existing tenant has leased the remaining 169,500 square feet on a rolling 90-day basis with landlord kick-out rights.
Total executed leases commencing in 2026, which have terms of at least six months, total an aggregate of 1,052,775 square feet, representing 13.7% of total 2026 expirations.
Same store occupancy at June 30, 2025, was 95.0%, while total portfolio occupancy at June 30, 2025, was 94.6%. Total portfolio occupancy changes from last quarter include:
<ul>
<li>50-basis-point net positive impact from leasing in St. Louis;</li>
<li>40-basis-point net positive impact from leasing in Cleveland;</li>
<li>40-basis-point net positive impact from leasing in Cincinnati;</li>
<li>Net 30-basis-point positive impact from acquisitions activity in the quarter; and</li>
<li>Net negative 130 basis-point impact from known leasing roll-over in Memphis (for which replacement interest has been high). &nbsp;</li>
</ul>
Acquisition Activity During the second quarter of 2025, Plymouth closed on the acquisition of 22 industrial buildings totaling 2.05 million square feet for a total of $204.7 million. Together, these properties are 97.1% leased and feature a weighted average remaining lease term of 2.6 years. The second quarter activity comprises the following:
<ul>
<li>100,420 square foot industrial building in southwest Atlanta, Georgia for $11.7 million at an expected initial net operating income ("NOI") yield of 6.95%; and</li>
<li>1.95 million square foot industrial portfolio encompassing 21 buildings located across Columbus, Cincinnati, and Cleveland for $193.0 million.</li>
</ul>
The Company used its existing unsecured line of credit to fund the abovementioned acquisitions. As of July 8, 2025, there is approximately $285.8 million of capacity on the line of credit.
Capital Markets Activity Under the Company's previously announced share repurchase program, through June 30, 2025, the Company has acquired and settled 805,394 shares of common stock at an average price per share of approximately $16.26.

PLYM

Plymouth Industrial Leases Nearly 5.8M Sq. Ft. in 2025, Rents Rise 13% on Renewals

<ul>
<li>More Than Doubles H2O America's Connections in Texas and Increases Exposure to High Growth Houston Region</li>
<li>Drives Scale, Increases Financial and Operational Diversification, and Enhances Value and Reliability for Customers, Communities, and All Stakeholders</li>
<li>Transaction Expected to be Accretive to Long-Term EPS Growth Rate; Texas Projected to Become Second Largest Utility Operation of H2O America by 20281</li>
<li>Company to Host Investor Webcast Today at 5:30 a.m. PT / 7:30 a.m. CT / 8:30 a.m. ET; Files Investor Presentation Highlighting Benefits of Proposed Combination</li>
</ul>

H2O America Acquires Quadvest In $540M Deal, More Than Doubling Texas Connections

Keybanc analyst Sophie Karp upgrades Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from Underweight to Sector Weight.

Upgrades

Analyst Ratings

Keybanc Upgrades Sunrun to Sector Weight

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amylyx.com%2F&amp;esheet=54286814&amp;newsitemid=20250708428715&amp;lan=en-US&amp;anchor=Amylyx+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=603300247059cb367a81bfc1bb8c81dc">Amylyx Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) ("Amylyx" or the "Company") today announced that it will host an investor event at the Endocrine Society's annual meeting (ENDO 2025) on Sunday, July 13, 2025, at 6:00 p.m. PT, both in-person in San Francisco, California and virtually. Speakers will discuss the current burden of post-bariatric hypoglycemia (PBH) and background on avexitide, a potential first-in-class GLP-1 receptor antagonist with FDA breakthrough therapy designation. Speakers will also review new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide in post-bariatric hypoglycemia, which will be presented during ENDO 2025. These data include composite rates of Level 2 and 3 hypoglycemic events in both trials as well as new pharmacokinetic (PK) and pharmacodynamic (PD) data demonstrating continuous pharmacologic activity of the 90 mg once daily dose regimen for a 24-hour period.
Amylyx' management team will be joined by the following experts at the event:
<ul>
<li>Marilyn Tan, MD, FACE, Principal Investigator of the LUCIDITY clinical trial, Co-Lead Investigator of the Phase 2 PREVENT Clinical Trial, and Clinical Associate Professor of Medicine at Stanford University School of Medicine</li>
<li>Helen Lawler, MD, Investigator on the LUCIDITY Clinical Trial, Co-Lead Investigator of the Phase 2 PREVENT Clinical Trial, and Associate Professor of Medicine in Endocrinology at University of Colorado at Denver School of Medicine</li>
<li>Colleen Craig, MD, Co-lead Investigator of Proof-of-Concept and First-in-Human Studies of Avexitide in PBH, led the avexitide development program during the Phase 2 PREVENT Clinical Trial, and Scientific Advisor and Consultant for Amylyx</li>
</ul>

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Amylyx to Spotlight Breakthrough Hypoglycemia Drug Avexitide at ENDO 2025 Investor Event

ADAG

Adagene Partners With ConjugateBio To Advance Bispecific Antibody Drug Conjugates Using Proprietary Antibody

PROK

ProKidney Reports Reports Statistically And Clinically Significant And Clinically Meaningful Results From Group 1 Modified Intent-To-Treat Population Of Phase 2 REGEN-007 Trial In Patients With CKD And Diabetes

<a href="https://www.globenewswire.com/Tracker?data=HPt9334Sk6sl9CV8M8CI3b_Pylq0SyAs_fh_RNpGc6aSmCQP_HnbSKuFUoQo_nUxWPw0D4zc-844HYk1PlFyQOW45NPrBZD8MjDHX7u7RCw=">Upstream Bio, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the first patient has been dosed in the Company's Phase 2 clinical trial evaluating verekitug in patients with COPD, broadening the global development program for verekitug into a third indication.
Verekitug is a novel antibody antagonist of the Thymic Stromal Lymphopoietin (TSLP) receptor, a key driver of the inflammatory response in allergic and inflammatory diseases such as asthma, where agents targeting TSLP have demonstrated clinical benefits.
VENTURE (<a href="https://www.globenewswire.com/Tracker?data=5eGs73-MT3S5voM1JghBbOl0Q7PGWIvRYDYBbb1VCdRJWAWp3TtNiJKjlvq05oMFP5Sm2-tYnXrj_V1EdVwUotlNyJeuXpUUWj2M4fovkAHLaiNxozrMp7PD5W7yK9cN">NCT06981078</a>) is a randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of verekitug in approximately 670 adults with moderate-to-severe COPD. Participants will be randomized to receive verekitug at doses of 100 mg once every 12 weeks, 400 mg once every 24 weeks, or placebo, over treatment periods of between 60 weeks and up to 108 weeks.
The primary endpoint of the study is the annualized rate of moderate or severe COPD exacerbations. Secondary endpoints include changes in participants' day-to-day symptoms as well as measures of lung function, such as forced expiratory volume in one second (FEV₁). Upstream Bio has designed this trial using endpoints that, pending interactions with regulatory authorities, could produce data to support submissions for product approval. The trial is enrolling patients regardless of blood eosinophil count, with the primary analysis focusing on those with elevated eosinophils at screening. Patients without elevated eosinophils at screening will be included to facilitate exploratory analyses of verekitug's efficacy in this population.
This COPD trial is part of the broader development program for verekitug that includes separate ongoing Phase 2 studies in CRSwNP and severe asthma. Upstream Bio completed enrollment in the Phase 2 trials in CRSwNP in January 2025 and in severe asthma in June 2025 and expects top-line data readouts in the third quarter of 2025 and the first quarter of 2026, respectively.

Upstream Bio Doses First COPD Patient in Phase 2 Trial for Anti-Inflammatory Drug Verekitug

Cryptourrencies are drifting upwards on Tuesday morning as markets expect further tariff-related news from the White House.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$108,823.13</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,563.84</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$151.17</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.29</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1697&nbsp;</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001184&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transcation increased by 95.4% and 312.2%, respectively. Daily active addresses are up by 14.3% and 0.08%, respectively.</li>
<li>Coinglass data shows 74,847 traders were liquidated in the past 24 hours for $162.83 million.</li>
<li>SoSoValue data shows net inflows of $216.6 million into spot Bitcoin ETFs on Monday. Spot Ethereum ETFs saw net inflows of $62.1 million.</li>
</ul>
Trader Notes: Altcoin Sherpa <a href="https://x.com/AltcoinSherpa/status/1942514777508438312">noted</a> Bitcoin has been stuck in a tight range for nearly two months. 
While short-term volatility remains choppy, he believes a breakout to new all-time highs could still materialize in July. 
The safer move is to wait, he said, though skilled traders are already positioned for the upside.
Daan Crypto Trades pointed out BTC's sluggish start to both the month and quarter is typical behavior, with price action bouncing between the Weekly and Monthly/Quarterly opens. 
He expects Bitcoin to remain in this consolidation range for another day or two. Despite geopolitical headline risks like tariff shocks, he said, "the market seems relatively unaffected."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> Choppy start of the month &amp; quarter as we usually see. Currently stuck between the Weekly Open and the Monthly/Quarterly Open. Good chance we stick around this area for a day or two more before finally choosing a direction. Still some headline risk here and there with the… <a href="https://t.co/3TgMDWQ8FG">pic.twitter.com/3TgMDWQ8FG</a>
&mdash; Daan Crypto Trades (@DaanCrypto) <a href="https://twitter.com/DaanCrypto/status/1942486315263483955?ref_src=twsrc%5Etfw">July 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Ted Labs co-founder Niels <a href="https://x.com/Web3Niels/status/1942513115339317755">sees</a> XRP as a potential early altseason signal. 
The coin is close to breaking out of a 7-month downtrend, and with RSI already breaking out, a weekly close above $2.40 could ignite a broader altcoin surge. 
He emphasized that historically, XRP breakouts have often preceded full-blown altseasons.
CryptoBatman observed Ethereum forming a megaphone pattern, signaling an upcoming breakout attempt. 
The next major resistance levels to watch are $3,500 and $4,200. A clean break above these could trigger a wider altcoin rally.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a> is gearing up for another run with this megaphone pattern shaping up. The first hurdle is the resistance at $3500, then the major resistance at $4,200. Altcoins will explode right after. Buckle up. <a href="https://t.co/0I3kPTPYQW">pic.twitter.com/0I3kPTPYQW</a>
&mdash; BATMAN &#x26a1; (@CryptosBatman) <a href="https://twitter.com/CryptosBatman/status/1942512056420425981?ref_src=twsrc%5Etfw">July 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Tardigrade <a href="https://x.com/TATrader_Alan/status/1942509254243729728">highlighted </a>Dogecoin's position inside an ascending broadening wedge on the weekly chart. DOGE is also contending with a parallel descending resistance trendline. A breakout here could indicate rising volatility and a possible strong upside continuation.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46272572/scottie-pippen-is-watching-bitcoin-xrp-dogecoin-and-what-else">Scottie Pippen Is Watching Bitcoin, XRP, Dogecoin&#8230;And What Else?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Hold Steady As Tariff Letters Shake Up Markets

Rosenblatt analyst Kevin Cassidy maintains Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy and maintains $5 price target.

Price Target

Rosenblatt Maintains Buy on Canaan, Maintains $5 Price Target

BlackRock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) will release earnings results for the second quarter, before the <a href="https://www.benzinga.com/quote/BLK/earnings">opening bell on Tuesday, July 15</a>.
Analysts expect the New York-based company to report quarterly earnings at $10.60 per share, up from $10.36 per share in the year-ago period. BlackRock projects to report quarterly revenue of $5.41 billion, compared to $4.80 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 7, BlackRock announced plans to acquire ElmTree Funds.
BlackRock shares fell 0.6% to close at $1,075.97 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/blk/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Wells Fargo analyst Michael Brown maintained an Overweight rating and raised the price target from $1,105 to $1,180 on July 3, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Mike Cyprys maintained an Overweight rating and boosted the price target from $1,111 to $1,164 on July 2, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Goldman Sachs analyst Alexander Blostein maintained a Buy rating and boosted the price target from $994 to $1,115 on June 27, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Argus Research analyst Stephen Biggar maintained a Buy rating and raised the price target from $1,028 to $1,090 on June 17, 2025. This analyst has an accuracy rate of 73%.</li>
<li>UBS analyst Brennan Hawken maintained a Neutral rating and cut the price target from $1,010 to $980 on April 16, 2025. This analyst has an accuracy rate of 73%</li>
</ul>
Considering buying BLK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/blk/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="594" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08024135/image-1-14-1024x594.png" alt="" class="wp-image-975869" style="width:642px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08024135/image-1-14-1024x594.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08024135/image-1-14-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08024135/image-1-14-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08024135/image-1-14.png 1123w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46271576/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-8">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

Top Wall Street Forecasters Revamp BlackRock Expectations Ahead Of Q2 Earnings

HC Wainwright &amp; Co. analyst Scott Buck maintains BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) with a Buy and raises the price target from $20 to $28.

BlackSky Technology Inc. Class A Common Stock

BKSY

HC Wainwright & Co. Maintains Buy on BlackSky Technology, Raises Price Target to $28

GRMN

Garmin Launches Force Current, First Hands-Free Kayak Trolling Motor With Wireless Throttle and Steering for Unmatched Fishing Control

BlackRock Inc.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) iShares Bitcoin Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) has surpassed Strategy Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) holdings, accumulating nearly 700,000 BTC worth approximately $75.8 billion and capturing 3.32% of Bitcoin&#8217;s total supply, according to Bitcoin Treasuries data.
What Happened: The milestone marks a significant shift in corporate Bitcoin ownership after just 18 months of trading. ETF Institute Co-Founder Nate Geraci called the achievement &#8220;ridiculous&#8221; in a Monday X post, highlighting IBIT&#8217;s rapid accumulation pace.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">New milestone… iShares Bitcoin ETF now holds over 700,000 btc. &#x2A;700,000&#x2A; Did this in 18 months. Ridiculous.
&mdash; Nate Geraci (@NateGeraci) <a href="https://twitter.com/NateGeraci/status/1942402697388294356?ref_src=twsrc%5Etfw">July 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
MicroStrategy, led by Executive Chairman Michael Saylor, holds 597,325 BTC valued at $64.8 billion with an average cost basis of $70,982 per coin. The business intelligence firm pioneered the corporate Bitcoin treasury strategy and maintains $22.6 billion in <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46281239/strategy-launches-4-2-billion-offering-to-fuel-further-bitcoin-accumulation">unrealized profits from its $42.4 billion investment</a>.
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46291389/us-stocks-likely-to-open-mixed-as-trump-issues-tariff-letters-experts-peg-ai-investments-as-durable-drivers-of-returns">US Stocks Likely To Open Mixed As Trump Issues Tariff Letters: Experts Peg AI Investments As &#8216;Durable Drivers Of Returns&#8217;</a>
Why It Matters: IBIT now generates an estimated $187.2 million in annual fees, <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46228970/blackrocks-bitcoin-etf-surpasses-sp-500-etf-in-revenue-as-xrp-dogecoin-etf-approval-predicted-to-follow-soon">surpassing revenue from BlackRock&#8217;s Core S&amp;P 500 ETF</a>, according to VanEck&#8216;s Head of Digital Assets Research Matthew Sigel. The Bitcoin ETF commands 55% of the Bitcoin ETF market share with over $52 billion in cumulative inflows.
MicroStrategy announced Monday a $4.2 billion at-the-market offering of Series A Perpetual Stride Preferred Stock to fund additional Bitcoin purchases. The move is part of the company&#8217;s expanded &#8220;42/42&#8221; capital plan targeting $84 billion in Bitcoin acquisitions by 2027, <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46281239/strategy-launches-4-2-billion-offering-to-fuel-further-bitcoin-accumulation">which is 38% complete</a>.
The corporate Bitcoin landscape continues evolving as Japanese tech company Metaplanet recently surpassed Coinbase Global Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) holdings with 10,000 BTC, demonstrating growing institutional adoption <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45957733/metaplanet-surpasses-coinbase-in-bitcoin-holdings-with-117-million-purchase-japans-crypto-giant-now-targets-1-of-btc-supply-by-2027">beyond traditional treasury strategies</a>.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asia/25/07/46290263/is-china-dodging-us-tariffs-direct-exports-to-america-plunge-43-as-vietnam-and-indonesia-see-big-spurts-report">Is China Dodging US Tariffs? Direct Exports To America Plunge 43% As Vietnam And Indonesia See Big Spurts: Report</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Tada Images / Shutterstock.com

Equities

ETFs

COIN

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

IBIT

MSTR

BlackRock's Bitcoin ETF Just Overtook Michael Saylor's MSTR — Now Holds Nearly 700,000 BTC

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Buy and maintains $81 price target.

Reiteration

CRSP

Needham Reiterates Buy on CRISPR Therapeutics, Maintains $81 Price Target

RiverNorth Marketplace Lending Corporation Common Stock

RiverNorth Capital and Income Fund Announces Preliminary Results of Oversubscribed Rights Offering, Expects $15.9M Gross Proceeds From 1.1M New Shares at $14.39 Each

ET-600 is a proprietary formulation of desmopressin oral solution developed for the treatment of central diabetes insipidius, also known as arginine vasopressin deficiency (AVP-D). The company has been issued a patent for ET-600's formulation that extends to 2044 and has an additional patent application under review by the United States Patent and Trademark Office. AVP-D is estimated to impact approximately 3,000 pediatric patients in the United States.

Health Care

ETON

The FDA Has Accepted Eton Pharmaceuticals' New Drug Application For ET-600, A Proprietary, Patented Formulation Of Desmopressin Oral Solution, For Review And Assigned A Prescription Drug User Fee Act Target Action Date Of February 25, 2026

Pump.fun may be one of the most polarizing platforms in crypto, but its financials are <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45775027/pump-funs-1b-token-plan-risks-undermining-solana-defi-fueling-meme-coin-scams-experts-warn">hard to ignore</a>.
In a valuation breakdown, 10x Research concludes that the Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)-based memecoin launchpad&#8217;s rumored $4 billion valuation, leaked via a now-deleted token sale <a href="https://x.com/cryptolyxe/status/1942311062256377929?s=46&amp;t=MuRujqZUAz3TQE1vmr3c6A">page</a> on Gate.io, still appears "relatively cheap" given its 2025 revenue performance.
According to the report, Pump.fun has generated $398 million in revenue year-to-date, far surpassing on-chain rival Raydium (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">RAY</a>), which earned $52 million during the same period despite facilitating more than 10 times the trading volume. 
This revenue lead stems from Pump.fun's flat 1% fee on all bonding-curve token trades, giving it a high-margin model that few platforms in the space can match.
Applying Raydium's current revenue multiple of 11.5x to Pump.fun's annualized $796 million revenue implies a potential valuation of $9.1 billion. 
The $4 billion figure, based on the planned sale of 150 billion PUMP tokens at $0.004 each, translates to a multiple closer to 5x, which 10x frames as a bear-case valuation. 
"A $4 billion valuation appears relatively inexpensive," the report states, calling the pricing "conservative" given comparative market dynamics.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46259970/why-nano-labs-wants-to-control-a-big-chunk-of-binance-coins-circulating-supply">Why Nano Labs Wants To Control A Big Chunk Of Binance Coin&#8217;s Circulating Supply</a>
The report comes after Gate.io briefly published, then removed, a pre-sale page showing a public token offering scheduled for July 12. 
The sale would have raised $600 million from the release of 150 billion tokens, representing 15% of the total 1 trillion supply. 
The page described it as Pump.fun's "first official public token sale," but its removal has fueled speculation and confusion. 
A support message from Gate.io <a href="https://x.com/support_gateio/status/1942369211432722670">mentioned </a>"negotiations" between the exchange and the project, and confirmed that there is "no confirmed date or announcement for its reopening."
Despite volatility and reputational baggage surrounding memecoins, 10x points to Pump.fun's sticky user base, 729,000 weekly users and stable monthly revenues of $25–$30 million, as signals of resilience. 
Even with a 66% revenue drop from January to May and declining daily token launches, the platform continues to outperform Raydium in revenue by nearly 8x.
Importantly, the platform's move to launch its own AMM, PumpSwap, has allowed it to capture full fee revenue and further reduce reliance on Raydium, with whom it once had a mutually beneficial migration agreement. 
That relationship soured earlier this year, culminating in Raydium launching its own memecoin incubator, LaunchLab, just two days before PumpSwap went live.
While critics have noted that 98% of tokens launched on Pump.fun either fail or exhibit fraudulent behavior and that over 1,700 wallets lost more than $100,000 the revenue engine powering the protocol remains intact. 
Of the 4.26 million wallets active on the platform, more than half ended up with minor losses, while only 311 netted over $1 million in profit.
Still, 10x suggests that market skepticism tied to Pump.fun's memecoin-centric identity could be masking its underlying value. 
"If the $4–$12 billion valuation range materializes," the report says, "early positioning could provide asymmetric upside."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46259948/bitcoin-etfs-just-pulled-in-600-million-in-a-day-is-a-major-price-breakout-coming-next">Bitcoin ETFs Just Pulled In $600 Million In A Day—Is A Major Price Breakout Coming Next?</a></li>
</ul>
Image: Shutterstock

Comments

Phillips Edison & Co

Phillips Edison & Co (PECO) Options

Phillips Edison & Co (NASDAQ:PECO) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL